Novavax Second Quarter 2023 Financial Results | Novavax Investor Relations

Skip to main content

For U.S. residents only: Nuvaxovid is now available. Find a location near you.

Investors
Newsroom
Blog
People & Culture

Science & Technology
Products & Pipeline
- Products
- Pipeline
Partnerships
About Us

For U.S. residents only: Nuvaxovid is now available. Find a location near you.

Science & Technology
Products & Pipeline
- Products
- Pipeline
Partnerships
About Us

Investors
Newsroom
Blog
People & Culture

Novavax Second Quarter 2023 Financial Results

Tuesday, August 8, 2023

8:30am EDT

Science & Technology

Overview
Technology platform
Matrix-M® adjuvant
Publications

Products & Pipeline

Products
Pipeline

Partnerships

Partner information

About Us

Our company
Our leadership
Novavax Sweden
Sustainability

Investors

Investors hub
Sign up for investor alerts

Newsroom

News and media
Perspectives & Insights
Press assets

Scientific Community

Global medical information

People & Culture

Working at Novavax
Jobs

Contact Us

Connect with us

COVID-19

Global authorization site for Novavax COVID-19 Vaccine

Science & Technology

Overview
Technology platform
Matrix-M® adjuvant
Publications

Products & Pipeline

Products
Pipeline

Partnerships

Partner information

About Us

Our company
Our leadership
Novavax Sweden
Sustainability

Investors

Investors hub
Sign up for investor alerts

Newsroom

News and media
Perspectives & Insights
Press assets

Scientific Community

Global medical information

People & Culture

Working at Novavax
Jobs

Contact Us

Connect with us

COVID-19

Global authorization site for Novavax COVID-19 Vaccine

Terms & Policies Center
Terms & Conditions
Privacy Policy
Your Privacy Choices
Collective patient information (French)
Sitemap

The scientific images on this website are generated or enhanced using artificial intelligence. These visuals are for illustrative purposes only. Illustrations of Matrix-M and Protein Nanoparticles are visual representations only.

©2025 Novavax. All rights reserved.

You are leaving Novavax.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Novavax provides this link as a service to website visitors. Novavax is not responsible for the privacy policy of any third-party websites.

You are being redirected to the Nuvaxovid^TM website, now managed by Sanofi.

Nuvaxovid^TM information is now managed by Sanofi. If you are a patient based in the US, please click the "Continue" button below to proceed. You will be leaving the Novavax site and Sanofi’s privacy policy will apply. Novavax is not responsible for the privacy practices or content of third-party websites.